Title
Category
Credits
Event date
Cost
  • Oncology
  • ANCC
  • Participation
03/25/2021
$0.00
The objective of this activity is to provide evidence-based information on the latest developments for the use of Bruton’s tyrosine kinase (BTK) inhibitors in patients with chronic lymphocytic leukemia (CLL). Given the demonstrated clinical benefit of BTKi therapy and its advantages over chemotherapy, it is essential for patients that the adoption of BTKi therapy continues to accelerate. Optimizing patient adherence to oral BTKis is vital to achieving efficacy and improving clinical outcomes.